Sun Pharmaceutical Industries announced that the U.S. Food and Drug Administration (FDA) has approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMYA™ selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor leading to inhibition of the release of pro-inflammatory cytokines and chemokines.

ILUMYA™ is administered at a dose of 100 mg by subcutaneous injection every 12 weeks, after the completion of initial doses at weeks 0 and 4. ILUMYA™ is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.

''With the approval of ILUMYA™ and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis,'' said Abhay Gandhi, President and Chief Executive Officer, North America, Sun Pharma. ''We are committed to working with all relevant stakeholders to make ILUMYA™ available to appropriate people with plaque psoriasis.''

Shares of the company gained Rs 10.2, or 2.02%, to trade at  Rs 514.90.  The total volume of shares traded  was  91,514 at the BSE (9.23 a.m., Thursday).